Navigation Links
Biomagnetics developed for use in new breast cancer tests
Date:2/29/2008

A team from UCL has developed a new medical device which will make the early detection of breast cancer more cost effective and easier to administer. The team - which won a prestigious Brian Mercer Feasibility Award from the Royal Society yesterday - plans to use magnetic nanoparticles and an extremely sensitive magnetometer called the HistoMag to detect cancerous cells in samples of breast tissue.

Each year 35,000 women are diagnosed with breast cancer in the UK and the testing programme is a massive undertaking, says Professor Quentin Pankhurst of the London Centre for Nanotechnology and the UCL Department of Physics & Astronomy. Until now, pathologists had to stain tissue samples with brown dyes to help them determine whether they were normal or cancerous. In terms of streamlining the process, the main problem is that all of the results are open to interpretation and each test has to be individually checked by a specialist.

At UCL weve been working in the relatively new area of biomagnetics to develop a technique which provides more quantitative and reliable results, whilst also enabling pathologists to identify abnormal tissue sections much more quickly.

Cancerous cells have a protein on their surface called HER2. We use a solution of HER2 antibodies, tagged with magnetic nanoparticles, to stain the tissue sample. Using the HistoMag we can detect the quantity of tagged antibodies which attach themselves to the HER2 protein, which in turn provides us with an accurate picture of the spread of cancerous cells.

By automating the process through which cancerous cells are detected and quantified, HistoMag will not only ease the pressure on pathologists but also help to identify the 15-30% of patients who are likely to benefit from being treated with the drug Herceptin. At a cost of 30,000 per patient per annum it is essential to target Herceptin at those women who will respond positively to it.

The team, led by Professor Pankhurst, is one of only seven groups to receive a Brian Mercer Feasibility Award from the Royal Society this year. The 25,000 award will enable the team to re-engineer the HistoMag, increasing its sensitivity before it goes on to clinical trials. Their goal is to make the device generally available to pathologists in 2010.


'/>"/>

Contact: Dave Weston
d.weston@ucl.ac.uk
44-020-767-97678
University College London
Source:Eurekalert  

Related biology news :

1. A new radiation therapy treatment developed for head and neck cancer patients
2. Model for the assembly of advanced, single-molecule-based electronic components developed at Pitt
3. New southernpeas developed by ARS, cooperators
4. New method developed to identify genetic determinants of Alzheimers disease
5. Newly created cancer stem cells could aid breast cancer research
6. Linchpin gene may be useful target for new breast cancer therapies
7. Dietary calcium could possibly prevent the spread of breast cancer to bone
8. Researchers find new gene linked to breast cancer
9. Analysis of breast and colon cancer genes finds many areas of differences between tumors
10. Genome update defines landscape of breast and colon cancers
11. AACR, BCRF award inaugural grants in translational breast cancer research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biomagnetics developed for use in new breast cancer tests
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of ... ended December 31, 2015. --> ... increased 2 percent compared to the comparable quarter last year to ... was $35.0 million, or $0.93 per diluted share. ... first quarter of fiscal 2016 grew 9 percent over the prior ...
(Date:1/25/2016)... BELL, Pa. , Jan. 25, 2016   Unisys Corporation ... recognition system at John F. Kennedy (JFK) International Airport, ... Border Protection (CBP) identify imposters attempting to enter ... do not belong to them. pilot testing of ... out initially at three terminals at JFK during January 2016. ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... Cupertino, CA (PRWEB) , ... February 08, 2016 ... ... and multilingual testing services, announced today the launch of its revamped and ... range of scalable language service solutions, the redesigned website will better communicate how ...
(Date:2/9/2016)... ... February 09, 2016 , ... Tunnell Consulting, Inc. announced that Frédéric Lefebvre ... will focus on acquiring new accounts and work closely with existing Tunnell clients throughout ... brings to our European clients more than 15 years of experience in the pharmaceutical ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... the years and Open Access publishing is one of the popular publication models ... open access journals and 3000+ International Conferences across the ...
(Date:2/9/2016)... HOUSTON , Feb. 9, 2016 /PRNewswire/ ... virus-driven immunotherapies for cancer, announced that its ... the European Commission as an orphan medicinal ... the deadliest form of glioma, strikes approximately ... and EU. http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
Breaking Biology Technology: